Ontology highlight
ABSTRACT:
INSTRUMENT(S): TripleTOF 6600
ORGANISM(S): Homo Sapiens (ncbitaxon:9606)
SUBMITTER:
Dr. Bruce Reinhold
PROVIDER: MSV000089110 | MassIVE | Wed Mar 23 12:52:00 GMT 2022
REPOSITORIES: MassIVE

Nature cancer 20230710 7
Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is treated with ALK tyrosine kinase inhibitors (TKIs), but the lack of activity of immune checkpoint inhibitors (ICIs) is poorly understood. Here, we identified immunogenic ALK peptides to show that ICIs induced rejection of ALK<sup>+</sup> tumors in the flank but not in the lung. A single-peptide vaccination restored priming of ALK-specific CD8<sup>+</sup> T cells, eradicated lung tumors in combination with ALK TKIs ...[more]